In melanoma and glioblastoma, THY1 overexpression enhances tumor progression and immune suppression by activating cancer-associated fibroblasts (CAFs) and altering immune cell behavior in the tumor microenvironment [10, 11]. This evidence concerns the gene THY1 and neoplasm.